Year Founded
2015
Ownership
Private
Employees
~100
Therapeutic Areas
Infectious DiseasesOncology
Stage
Phase 2
Modalities
mRNA therapeutics

Providence Therapeutics General Information

Lead COVID-19 vaccine PTX-COVID19-B showed positive Phase 2 results matching Comirnaty. Planning Phase 3 booster study. Developing cancer vaccines using mRNA platform.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Calgary, Alberta
Canada

Drug Pipeline

PTX-COVID19-B
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Providence Therapeutics's pipeline data

Book a demo

Key Partnerships

Biological E, Everest Medicines, Emergent BioSolutions, Northern Therapeutics, University Health Network

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Providence Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Providence Therapeutics's complete valuation and funding history, request access »

Providence Therapeutics Investors

Bill & Melinda Gates Foundation (provided US$2.2 million in funding)
Investor Type: Venture Capital
Holding: Minority
Canadian government
Investor Type: Venture Capital
Holding: Minority